Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Companies

Set Alert for Companies

Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA

Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.

FDA Advertising, Marketing & Sales Policy & Regulation
Advertisement

Companies

Latest From Companies

Bayer's Weinand On Broadening Value-Based Pricing Views

Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.

Pricing Strategies Reimbursement

Korean Pharma Spawns US Cancer Biotech Startup

Dr. Benjamin R Cowen, COO of ImmunoMet Therapeutics, reveals how the Houston-based startup is developing OXPHOS inhibitors to treat drug resistant and relapse cancers.

Companies StartUps and SMEs

Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV

Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.

Commercial Companies

Bone Therapeutics Looks To ALLOB Data Progress

Following its IPO in 2015, Belgium's Bone Therapeutics has been making progress on its allogeneic osteoblastic cell product, ALLOB, which recently appointed CEO Thomas Lienard pegs as the company's most valuable platform. With the product currently in Phase II trials, Lienard shares his plans for the company.

Companies Research and Development Strategies

Clozel's CHF1bn Actelion Spin-Out Idorsia Awaits Janssen Buy-In

Upon completion of Johnson & Johnson's $30bn acquisition of Actelion, Jean-Paul Clozel, the latter's outgoing CEO, aims to build a new European biopharma big-hitter – Idorsia – with the earlier-stage assets Actelion leaves behind. He's hoping that J&J's Janssen will soon opt in to rights to its lead candidate. Idorsia is preparing to launch onto the Swiss Stock Exchange with CHF1bn in cash at inception.

Financing StartUps and SMEs

ARCH CV Signal Scuppers Blockbuster Hopes For Amgen/UCB's Evenity

New Phase III data for the novel osteoporosis therapy romosozumab are set to delay its approval, reduce its commercial potential and open the market to rivals.

Companies Clinical Trials
See All
UsernamePublicRestriction

Register